Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Oncotarget|October 22, 2014
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibitionEdward Allan R Sison, Daniel Magoon, Li Li, et al.
British Journal of Haematology|August 10, 2007
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cellsKyu-Tae Kim, Kristin Baird, Sean Davis, et al.
Plos One|April 22, 2014
Correlated miR-mRNA expression signatures of mouse hematopoietic stem and progenitor cell subsets predict "Stemness" and "Myeloid" interaction networksDiane Heiser, Yee Sun Tan, Ian Kaplan, et al.
Blood|January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoTakashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Cancer Research|May 3, 2006
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samplesObdulio Piloto, Bao Nguyen, David Huso, et al.
Signal Transduction and Targeted Therapy|May 24, 2021
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activationRuiqi Zhu, Li Li, Bao Nguyen, et al.
Blood|January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivoHayley Ma, Bao Nguyen, Li Li, et al.
British Journal of Haematology|March 16, 2007
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cellsLi Li, Obdulio Piloto, Kyu-Tae Kim, et al.
The Journal of Molecular Diagnostics : JMD|April 23, 2003
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assayKathleen M Murphy, Mark Levis, Michael J Hafez, et al.
Blood|July 22, 2006
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapySteven Knapper, Alan K Burnett, Tim Littlewood, et al.
Pageof 9